By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Daewon Pharmaceutical Co., Ltd. (003220.KS)

KSC Currency in KRW
₩13.05K
+₩30.00
+0.23%
Last Update: 10 Sept 2025, 06:30
₩279.71B
Market Cap
13.43
P/E Ratio (TTM)
2.30%
Forward Dividend Yield
₩12.37K - ₩16.78K
52 Week Range

003220.KS Stock Price Chart

Explore Daewon Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze 003220.KS price movements and trends.

003220.KS Company Profile

Discover essential business fundamentals and corporate details for Daewon Pharmaceutical Co., Ltd. (003220.KS) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

29 Sept 2005

Employees

1.26K

CEO

Seung-Ryel Baek

Description

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.

003220.KS Financial Timeline

Browse a chronological timeline of Daewon Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 May 2026

Upcoming earnings on 5 Feb 2026

Upcoming earnings on 12 Nov 2025

Earnings released on 12 Aug 2025

Earnings released on 14 May 2025

EPS came in at ₩250.00 falling short of the estimated ₩581.65 by -57.02%, while revenue for the quarter reached ₩157.83B , missing expectations by -4.69%.

Earnings released on 7 Feb 2025

EPS came in at -₩49.46 falling short of the estimated ₩253.44 by -119.52%, while revenue for the quarter reached ₩145.07B , missing expectations by -7.33%.

Dividend declared on 27 Dec 2024

A dividend of ₩300.00 per share was announced, adjusted to ₩300.00. The dividend was paid on 25 Apr 2025.

Earnings released on 14 Nov 2024

EPS came in at ₩316.63 falling short of the estimated ₩356.49 by -11.18%, while revenue for the quarter reached ₩156.83B , beating expectations by +4.90%.

Earnings released on 14 Aug 2024

EPS came in at -₩36.00 falling short of the estimated ₩568.73 by -106.33%, while revenue for the quarter reached ₩137.96B , missing expectations by -10.89%.

Earnings released on 16 May 2024

EPS came in at ₩436.00 surpassing the estimated ₩428.46 by +1.76%, while revenue for the quarter reached ₩158.30B , beating expectations by +13.44%.

Earnings released on 14 Mar 2024

EPS came in at ₩23.00 falling short of the estimated ₩403.73 by -94.30%, while revenue for the quarter reached ₩140.85B , beating expectations by +1.48%.

Dividend declared on 27 Dec 2023

A dividend of ₩300.00 per share was announced, adjusted to ₩300.00. The dividend was paid on 19 Apr 2024.

Earnings released on 14 Nov 2023

EPS came in at ₩252.00 falling short of the estimated ₩401.00 by -37.16%, while revenue for the quarter reached ₩128.98B , missing expectations by -0.09%.

Earnings released on 11 Aug 2023

EPS came in at ₩385.00 falling short of the estimated ₩401.97 by -4.22%, while revenue for the quarter reached ₩133.03B , beating expectations by +5.13%.

Earnings released on 15 May 2023

EPS came in at ₩445.80 , while revenue for the quarter reached ₩124.09B , missing expectations by -8.76%.

Earnings released on 9 Feb 2023

EPS came in at ₩141.40 , while revenue for the quarter reached ₩122.54B , missing expectations by -2.63%.

Dividend declared on 28 Dec 2022

A dividend of ₩350.00 per share was announced, adjusted to ₩350.00. The dividend was paid on 21 Apr 2023.

Earnings released on 11 Nov 2022

EPS came in at ₩504.99 , while revenue for the quarter reached ₩122.24B , beating expectations by +4.27%.

Earnings released on 16 Aug 2022

EPS came in at ₩348.96 , while revenue for the quarter reached ₩117.05B , beating expectations by +1.60%.

Earnings released on 16 May 2022

EPS came in at ₩495.00 , while revenue for the quarter reached ₩117.06B , beating expectations by +14.26%.

Stock split effective on 7 Mar 2022

Shares were split 103 : 100 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 10 Feb 2022

EPS came in at ₩270.87 , while revenue for the quarter reached ₩100.96B , beating expectations by +11.74%.

Dividend declared on 29 Dec 2021

A dividend of ₩200.00 per share was announced, adjusted to ₩194.17. The dividend was paid on 22 Apr 2022.

Earnings released on 15 Nov 2021

EPS came in at ₩295.15 , while revenue for the quarter reached ₩90.52B .

Earnings released on 17 Aug 2021

EPS came in at ₩143.69 , while revenue for the quarter reached ₩87.70B .

Earnings released on 17 May 2021

EPS came in at -₩380.58 , while revenue for the quarter reached ₩74.99B .

Stock split effective on 18 Feb 2021

Shares were split 21 : 20 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 4 Feb 2021

EPS came in at ₩104.61 , while revenue for the quarter reached ₩77.47B .

Dividend declared on 29 Dec 2020

A dividend of ₩152.38 per share was announced, adjusted to ₩147.94. The dividend was paid on 16 Apr 2021.

Earnings released on 13 Nov 2020

EPS came in at ₩161.81 , while revenue for the quarter reached ₩75.71B .

003220.KS Stock Performance

Access detailed 003220.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run